A long-acting timolol transdermal preparation and its application in hemangioma

A technology of timolol and transdermal preparation, which is applied to timolol long-acting transdermal preparation and its application in hemangioma, can solve the problems of large side effects, adverse reactions, scars left, etc. The effect of drug dosage, improving treatment effect, and promoting efficiency

Active Publication Date: 2017-06-13
BEIJING MERSON PHARMA CO LTD
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Traditional treatment methods such as oral corticosteroids, local injection of pingyangmycin, surgery, laser and freezing, etc., or because of the side effects of drugs, or because the treatment process is more painful, there may be a series of adverse effects such as scars and tissue atrophy in the later stage. Reaction, so that its clinical application is limited, the overall efficacy is not satisfactory
The application of Timolol is a revolutionary change in the treatment of hemangiomas. It is a β-adrenergic receptor antagonist. It was previously used to treat hypertension, angina pectoris, and tachycardia. It is completely clear that high-dose external application of timolol in the treatment of severe infantile hemangiomas has a rapid and obvious curative effect, is well tolerated by children, and can significantly shorten the course of hemangiomas, but there are still adverse reactions, including bradycardia and hypotension , bronchospasm, hypoglycemia, drowsiness or insomnia, nightmares, decreased appetite, sweating, etc.
In general, timolol may become the first-line drug for the treatment of severe and complicated infantile hemangiomas, but oral timolol has potential cardiotoxic side effects and adverse reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A long-acting timolol transdermal preparation and its application in hemangioma
  • A long-acting timolol transdermal preparation and its application in hemangioma
  • A long-acting timolol transdermal preparation and its application in hemangioma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1 Preparation of timolol hydrogel long-acting transdermal preparation (1)

[0027] The small molecule drug timolol is prepared into a nano / micropowder hydrogel transdermal preparation, and the preparation process is as follows:

[0028] (1) Accurately weigh 10g of timolol and dissolve it in 100mL of water, then add 20g of porous silica nanoparticles, stir overnight to make timolol fully adsorbed in the silica particles, centrifuge to remove the supernatant, and then fully Washing, then freeze-drying to form timolol nano / micropowder medicine, the particle diameter of medicine is 20~100000 nanometers;

[0029] (2) Prepare a hydrogel solution with 12% by weight of polyvinyl alcohol (molecular weight: 40,000) and 1% by weight of polyethylene glycol (molecular weight: 400);

[0030] (3) Disperse the timolol nano / micropowder drug prepared in step (1) in the hydrogel solution prepared in step (2) according to the weight ratio of 1:1, and add benzene with a final weigh...

Embodiment 2

[0047] Example 2 Preparation of timolol nano hydrogel long-acting transdermal preparation (2)

[0048] The small molecule drug timolol is prepared into a nano-hydrogel long-acting transdermal preparation, and the preparation process is as follows:

[0049] (1) Accurately weigh 0.2g of timolol and dissolve it in 10mL of water, then add 1g of porous hydroxyapatite nanoparticles, stir overnight to make timolol fully adsorbed in the hydroxyapatite particles, and centrifuge to remove the supernatant , fully washed, and then freeze-dried to form timolol nano-medicine, the particle size of the nano-medicine is 20-500 nanometers;

[0050] (2) Prepare a hydrogel solution with 4% by weight of polyvinyl alcohol (molecular weight: 40,000), 4% by weight of polyvinyl alcohol (molecular weight: 136,000), and 2% by weight of polyethylene glycol (molecular weight: 400) ;

[0051] (3) Disperse the timolol nanomedicine prepared in step (1) in the hydrogel solution prepared in step (2) accordin...

Embodiment 3

[0057] Example 3 Preparation of timolol nano hydrogel long-acting transdermal preparation (3)

[0058] The small molecule drug timolol is prepared into a nano-hydrogel long-acting transdermal preparation, and the preparation process is as follows:

[0059] (1) Accurately weigh 10g of timolol and dissolve it in 100mL of water, then add 40g of porous silver nanoparticles, stir overnight to make timolol fully adsorbed in the silver nanoparticles, centrifuge to remove the supernatant, then fully wash, and then Freeze-drying to form timolol nano-medicine, the particle size of nano-medicine is 10-1000 nanometers;

[0060] (2) Prepare a hydrogel solution with 8% by weight of sodium carboxymethylcellulose, 5% by weight of polyvinyl alcohol (molecular weight: 100,000), and 1.5% by weight of polyethylene glycol (molecular weight: 400);

[0061] (3) Disperse the timolol nanomedicine prepared in step (1) in the hydrogel solution prepared in step (2) according to the weight ratio of 1:10,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to a timolol long-acting transdermal preparation, the preparation process of which comprises: first preparing timolol into timolol nano-medicine or timolol micropowder, and then preparing timolol nano-medicine Or timolol micropowder is prepared into timolol hydrogel transdermal preparation, ointment transdermal preparation or microneedle transdermal preparation. The present invention also relates to the application of the above-mentioned medicine in the treatment of hemangioma. Using the medicine of the invention to treat infantile hemangioma can promote the efficiency of diseased cells to absorb medicine, improve the treatment effect, reduce the dosage of medicine, and have no adverse reaction in the treatment process.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a timolol long-acting transdermal preparation and its application in hemangioma. Background technique [0002] Infantile hemangioma (IH) is the most common benign tumor in childhood. It occurs in female infants and premature infants. It is characterized by rapid early postnatal hyperplasia followed by spontaneous slow regression. After natural regression, erythema, pigment changes, telangiectasia, atrophic scars, and fibrofatty tissue vegetations are often left locally, which affect the appearance to varying degrees. Since the presence of hemangioma can lead to serious appearance deformity and psychological disturbance, most parents urgently require early treatment. From the perspective of plastic surgery, the treatment of infantile hemangioma should be based on the principle of non-invasive, no scar and no secondary damage. [0003] Traditional treatment methods such as oral...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/06A61K9/00A61K31/5377A61P35/00
Inventor 袁伟恩郑家伟吴飞张凌
Owner BEIJING MERSON PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap